By Evans Matthews
In the high-stakes world of modern medicine, discovering a brand-new drug can take more than a decade and cost billions of dollars. Yet, sometimes the most powerful breakthroughs come not from entirely new compounds but from familiar medicines already sitting on pharmacy shelves. Drug repurposing, also called drug repositioning – is transforming healthcare by giving existing medications new life-saving roles.
Drug repurposing involves identifying new therapeutic uses for medicines that were originally developed for different conditions. Because these drugs have already passed many safety tests, researchers can move faster toward clinical use, potentially saving both time and resources.
“Repurposing drugs allows us to bypass some of the most time-consuming stages of drug development,” says pharmacologist Dr. Anita Reynolds of the Global Therapeutics Institute. “We already understand the safety profile of these medicines, which means we can focus on whether they work against new diseases.”
One of the most famous examples is Aspirin. Originally developed as a pain reliever, aspirin is now widely used to prevent heart attacks and strokes due to its blood-thinning properties. Another notable case is Sildenafil, which was initially studied for heart-related chest pain but later became a breakthrough treatment for erectile dysfunction under the brand Viagra.
Repurposed medicines have also played a crucial role in infectious disease treatment. During the global health emergency of COVID-19, scientists rapidly investigated existing drugs to see whether they could help manage the illness. One such drug was Dexamethasone, a decades-old steroid commonly used to treat inflammation. Clinical studies revealed that it significantly reduced mortality in severely ill COVID-19 patients requiring oxygen or ventilator support.
“Without repurposed drugs like dexamethasone, the early phase of the pandemic could have been even more devastating,” notes infectious disease specialist Dr. Luis Andrade. “It showed how valuable existing medicines can be in an emergency.”
The strategy is also reshaping cancer treatment. Some drugs originally designed for other diseases are now being tested for their ability to slow tumor growth. Researchers have discovered that certain medications used for diabetes, heart disease, or parasitic infections may influence cancer-related pathways in the body.
Artificial intelligence and big-data analysis are accelerating these discoveries. Scientists can now scan vast biomedical databases to identify unexpected links between existing drugs and diseases. These digital tools analyze gene activity, protein interactions, and clinical data to predict which medications might work in new therapeutic areas.
“Technology is changing the speed at which we can identify promising candidates,” explains biomedical data scientist Dr. Helena Okafor. “What once took years of trial and error can now be suggested by algorithms in weeks.”
Despite its promise, drug repurposing is not without challenges. Some pharmaceutical companies hesitate to invest heavily in repurposed drugs because the original patents may have expired, limiting financial incentives. Regulatory approval can also require new clinical trials to confirm effectiveness for the new condition.
Still, global health experts believe the approach will play an increasingly important role in medicine especially in low- and middle-income countries where access to new drugs can be limited.
“Repurposed medicines can dramatically expand treatment options worldwide,” says Dr. Reynolds. “When we find new uses for old drugs, we’re not just extending their life, we’re extending lives.”
English